Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094081 · ClinicalTrials.gov registry record · Phase 3
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 861
- Enrollment target
NCT00094081 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 861 participants.
The verdict
NCT00094081, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 861 participants
- Enrollment target
Study Summary
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
Interventions
- DRUG cisplatin
- PROCEDURE Radiation Therapy
- DRUG tirapazamine (SR259075)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094081
The ClinicalTrials.gov registry entry for NCT00094081 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 861 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00094081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00094081 about?
NCT00094081 is a clinical study titled "Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer". The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
What is the current status of trial NCT00094081?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 861 participants. The study started on 2002-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00094081?
The interventions under investigation include: cisplatin (DRUG), Radiation Therapy (PROCEDURE), tirapazamine (SR259075) (DRUG).
Who is sponsoring clinical trial NCT00094081?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.